---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-017958"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T03:21:04.844201+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharma Q1 net loss $61.3M; cash $318.2M; pipeline on track

## Summary
- Net loss of $61.3M ($0.56/share) vs $62.1M in Q1 2024; R&D expenses down to $35.9M.
- Cash, equivalents, investments $318.2M; operational runway into Q4 2026.
- Phase 2 RP-A501 for Danon disease ongoing; program update mid-2025, data mid-2026.
- Initial Phase 1 data for RP-A601 (PKP2-ACM) expected May 2025; IND for BAG3-DCM mid-2025.
- Rolling BLA for RP-L102 (Fanconi Anemia); final module late 2025/early 2026.

## SEC filing metadata
- accession: 0001140361-25-017958
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036125017958/0001140361-25-017958-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036125017958/ef20048651_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-017958
- JSON: https://secwatch.observer/filing/0001140361-25-017958.json
- Plain text: https://secwatch.observer/filing/0001140361-25-017958.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.